Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells

• Published in: Nutrition and cancer Vol. 31; no. 1; p. 8
• Main Authors: Wan, X.S. (University of Pennsylvania School of Medicine, Philadelphia, PA.), Hamilton, T.C, Ware, J.H, Donahue, J.J, Kennedy, A.R
• Format: Journal Article
• Language: English
• Published: United States 1998
• Subjects: CARCINOMA; CARCINOME; CELL CULTURE; Cell Death; Cell Division - drug effects; CELL LINES; Cell Survival; CELLS; CELLULE; CELULAS; Cisplatin - pharmacology; CLONOGENIC SURVIVAL; CRECIMIENTO; CROISSANCE; CULTIVO DE CELULAS; CULTURE DE CELLULE; Culture Media; DOSAGE EFFECTS; Drug Resistance, Neoplasm; Drug Synergism; DRUGS; EFECTOS DE DOSIFICACION; EFFET DOSE; ENFERMEDADES DE LOS OVARIOS; Female; GROWTH; Humans; INHIBICION; INHIBIDORES DE PROTEINASAS; INHIBITEUR DE PROTEINASES; INHIBITION; MALADIE DE L'OVAIRE; MEDICAMENT; MEDICAMENTOS; OVARIAN DISEASES; Ovarian Neoplasms - pathology; PRODUCTOS DE LA SOJA; PRODUIT A BASE DE SOJA; PROTEINASE INHIBITORS; RESISTANCE AUX PRODUITS CHIMIQUES; RESISTANCE TO CHEMICALS; RESISTENCIA A PRODUCTOS QUIMICOS; SINERGISMO; SOYBEAN PRODUCTS; SUPERVIVENCIA; SURVIE; SURVIVAL; SYNERGISM; SYNERGISME; TEMPS; TIEMPO; TIME; TOXICIDAD; TOXICITE; TOXICITY; Trypsin Inhibitor, Bowman-Birk Soybean - pharmacology; Tumor Cells, Cultured
• ISSN: 0163-5581; 1532-7914
• DOI: 10.1080/01635589809514672

Bowman-Birk inhibitor (BBI) is a soybean-derived anticarcinogenic protease inhibitor that was shown to potentiate the cytotoxicity of cisplatin in our previous studies. To assess the potential of BBI as a sensitizing agent for the chemotherapy of cisplatin-resistant cancers, we evaluated the effects of a soybean concentrate enriched in BBI (known as BBI concentrate or BBIC) on cell growth and clonogenic survival of a human ovarian cancer cell line, A2780, and its cisplatin-resistant sublines, C30 and C200. The presence of BBI and BBIC in the cell culture medium reduced the clonogenic survival of the A2780, C30, and C200 cells in a dose-dependent manner and enhanced cisplatin-induced growth inhibition and/or cytotoxicity. BBIC alone showed greater inhibitory effects on growth in the cisplatin-resistant cell lines. These results suggest that BBI and BBIC could be useful agents for the treatment of cancers, especially with cisplatin, in tumors resistant to this important anticancer agent